Table 3.
Clinical and treatment characteristics at initial bladder cancer diagnosis of BeWell Cohort, as of June 30, 2018, among participants in the regional cancer registry
| KPNC | KPSC | Totala | |
|---|---|---|---|
| N=588 N (%) | N=300 N (%) | N=888 N (%) | |
| Stageb | |||
| Ta | 413 (70.2) | 197 (67.0) | 610 (69.2) |
| Tis | 18 (3.1) | 11 (3.7) | 29 (3.3) |
| T1 | 157 (26.7) | 86 (29.3) | 243 (27.5) |
| Gradec | |||
| Low (LG) | 265 (45.1) | 149 (50.3) | 414 (46.8) |
| High (HG) | 315 (53.6) | 137 (46.3) | 452 (51.1) |
| Other (CIS) | 8 (1.4) | 10 (3.4) | 18 (2.0) |
| Stage/Gradeb,c | |||
| LG Ta | 251 (42.7) | 127 (43.9) | 378 (43.1) |
| LG T1 | 10 (1.7) | 20 (6.9) | 30 (3.4) |
| HG Ta | 160 (27.2) | 67 (23.2) | 227 (25.9) |
| HG T1 | 146 (24.8) | 64 (22.1) | 210 (23.9) |
| Tis | 21 (3.6) | 11 (3.8) | 32 (3.6) |
| Receipt of Initial TURBTd | |||
| Yes | 583 (99.2) | 251 (83.7) | 834 (93.9) |
| No | 5 (0.8) | 49 (16.3) | 54 (6.1) |
| Receipt of Re-TURBT (within 2 months of initial diagnosis)d | |||
| Yes | 131 (22.3) | 43 (14.3) | 174 (19.6) |
| No | 457 (77.7) | 257 (85.7) | 714 (80.4) |
| Receipt of Perioperative Chemotherapyd | |||
| No | 348 (59.2) | 240 (80.0) | 588 (66.2) |
| Yes | 240 (40.8) | 60 (20.0) | 300 (33.8) |
| Receipt of Induction Intravesical Therapyd | |||
| No | 336 (57.1) | 211 (70.3) | 547 (61.6) |
| Yes | 252 (42.9) | 89 (29.7) | 341 (38.4) |
a
Total unknown values: Stage n=6, Grade n=4, Stage/Grade n=11
b
Limited to stage data from KPNC Cancer Registry for cases diagnosed as of June 30, 2017 and the KPSC Cancer Registry for cases diagnosed as of Dec 31, 2016. Missing data were supplemented with chart review. If multiple bladder tumors for an individual were in the registry, the record with diagnosis date closest to the qualifying pathology date was selected.
c
From eligibility check chart review
d
From KP electronic data sources